Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders

Human Gene Therapy

Volumn 16, Issue 9, 2005, Pages 1028-1036

  Arkin, Lisa M ^a   Sondhi, Dolan ^a   Worgall, Stefan ^a   Suh, Lily Hyon K ^a   Hackett, Neil R ^a   Kaminsky, Stephen M ^a   Hosain, Syed A ^a   Souweidane, Mark M ^a   Kaplitt, Michael G ^a   Dyke, Jonathan P ^a   Heier, Linda A ^a   Ballon, Douglas J ^a   Shungu, Dikoma C ^a   Wisniewski, Krystyna E ^b   Greenwald, Bruce M ^a   Hollmann, Charleen ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PARVOVIRUS VECTOR;

ADULT; CENTRAL NERVOUS SYSTEM; CHILD; CHILD DEATH; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG SAFETY; ETHICS; EVIDENCE BASED MEDICINE; FAMILY; FATALITY; GENE TRANSFER; HUMAN; LIPOFUSCINOSIS; LYSOSOME STORAGE DISEASE; MEDICAL DECISION MAKING; NERVE DEGENERATION; NEURONAL CEROID LIPOFUSCINOSIS LATE INFANTILE TYPE; REVIEW; RISK BENEFIT ANALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

CLINICAL TRIALS, PHASE I; GENE THERAPY; HUMANS; MOTIVATION; NEURONAL CEROID-LIPOFUSCINOSES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SELECTION; RISK ASSESSMENT;

ADENO-ASSOCIATED VIRUS;

EID: 24944522335     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1028     Document Type: Review

References (65)

1. ACKERMAN, T.F. (1995). The ethics of phase I pediatric oncology trials. IRB 17, 1-5.
2. AGLIETTA, M., BERTOLINI, F., CARLO-STELLA, C., DE VINCENTIIS, A., LANATA, L., LEMOLI, R.M., OLIVIERI, A., SIENA, S., ZANON, P., and TURA, S. (1998). Ex vivo expansion of hematopoietic cells and their clinical use. Haematologica 83, 824-848.
3. ANAND, G. (2003). Clinical trials: For his sick kids, a father struggled to develop a cure. Wall Street Journal, August 26. http://online.wsj.com/public/ us (accessed August 2005).
4. APPLEBAUM, P.S. (2002). Clarifying the ethics of clinical research a path towards avoiding the therapeutic misconception. Am. J. Bioethics 2, 22.
5. BALICKI, D., and BEUTLER, E. (2002). Gene therapy of human disease. Medicine (Baltimore) 81, 69-86.
6. CHENG, S.H., and SMITH, A.E. (2003). Gene therapy progress and prospects: Gene therapy of lysosomal storage disorders. Gene Ther. 10, 1275-1281.
7. COSTANTINI, L.C., BAKOWSKA, J.C., BREAKEFIELD, X.O., and ISACSON, O. (2000). Gene therapy in the CNS. Gene Ther. 7, 93-109.
8. COYNE, C.A., XU, R., RAICH, P., PLOMER, K., DIGNAN, M., WENZEL, L.B., FAIRCLOUGH, D., HABERMANN, T., SCHNELL, L., QUELLA, S., and CELLA, D. (2003). Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: A study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 21, 836-842.
9. CRYSTAL, R.G., SONDHI, D., HACKETT, N.R., KAMINSKY, S.M., WORGALL, S., STIEG, P., SOUWEIDANE, M., HOSAIN, S., HEIER, L., BALLON, D., DINNER, M., WISNIEWSKI, K., KAPLITT, M., GREENWALD, B.M., HOWELL, J.D., STRYBING, K., DYKE, J., and VOSS, H. (2004). Clinical protocol: Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. 15, 1131-1154.
10. DAUGHERTY, C.K. (1999). Impact of therapeutic research on informed consent and the ethics of clinical trials: A medical oncology perspective. J. Clin. Oncol. 17, 1601-1617.
11. DOCKSER MARCUS, A. (2002). Hiring your own scientist to find a cure: Families of terminally ill set up research foundations. Wall Street Journal, April 25. http://online.wsj.com/public/us (accessed August 2005).
12. EDELSTEIN, M.L., ABEDI, M.R., WIXON, J., and EDELSTEIN, R.M. (2004). Gene therapy clinical trials worldwide 1989-2004: An overview. J. Gene Med. 6, 597-602.
13. EMANUEL, E.J., WENDLER, D., and GRADY, C. (2000). What makes clinical research ethical? JAMA 283, 2701-2711.
14. ESTLIN, E.J., COTTERILL, S., PRATT, C.B., PEARSON, A.D., and BERNSTEIN, M. (2000). Phase I trials in pediatric oncology: Perceptions of pediatricians from the United Kingdom Children's Cancer Study Group and the Pediatric Oncology Group. J. Clin. Oncol. 18, 1900-1905.
15. FURMAN, W.L., PRATT, C.B., RIVERA, G.K., KRISCHER, J.P., KAMEN, B.A., and VIETTI, T.J. (1989). Mortality in pediatric phase I clinical trials. J. Natl. Cancer Inst. 81, 1193-1194.
16. GOLDBERG, C. (2004). Fragile promise: Parents push scientists to cure son's disease. Boston Globe, July 20. http://www.boston.com/tools/archives/ (accessed August 2005).
17. GRADY, D. (2004). After baby's grim diagnosis, parents try drastic treatment. New York Times, December 19. http://query.nytimes. com/search/advanced (accessed August 2005).
18. GRADY, D. (2005). Despite desperate measures, baby with rare disease dies. New York Times, February 4. http://query.nytimes.com/search/advanced (accessed August 2005).
19. GROSSMAN, S.A., PIANTADOSI, S., and COVAHEY, C. (1994). Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? J. Clin. Oncol. 12, 2211-2215.
20. HACEIN-BEY-ABINA, S., LE DEIST, F., CARLIER, F., BOUNEAUD, C., HUE, C., DE VILLARTAY, J.P., THRASHER, A.J., WULFFRAAT, N., SORENSEN, R., DUPUIS-GIROD, S., FISCHER, A., DAVIES, E.G., KUIS, W., LEIVA, L., and CAVAZZANA-CALVO, M. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193.
21. HADLEY, C. (2004). The power of giving. EMBO Rep. 5, 751-754.
22. HAFFNER, M.E. (2004). Developing treatments for inborn errors: Incentives available to the clinician. Mol. Genet. Metab. 81(Suppl. 1), S63-S66.
23. HALE, V. (2004). Creating more paths to hope. Newsweek, December 6. http://www.msnbc.msn.com/id/3668484/site/newsweek/ (accessed August 2005).
24. HENDERSON, G.E., DAVIS, A.M., KING, N.M., EASTER, M.M., ZIMMER, C.R., ROTHSCHILD, B.B., WILFOND, B.S., NELSON, O.K., and CHURCHILL, L.R. (2004). Uncertain benefit: Investigators' views and communications in early phase gene transfer trials. Mol. Ther. 10, 225-231.
25. HENIG, R.M. (2005). Racing with Sam. New York Times, January 30. http://query.nytimes.com/search/advanced (accessed August 2005).
26. HORNG, S., EMANUEL, E.J., WILFOND, B., RACKOFF, J., MARTZ, K., and GRADY, C. (2002). Descriptions of benefits and risks in consent forms for phase I oncology trials. N. Engl. J. Med. 347, 2134-2140.
27. IOANNIDIS, J.P. (2004). Materializing research promises: Opportunities, priorities and conflicts in translational medicine. J. Transl. Med. 2, 5.
28. IRIBARNE, A. (2003). MSJAMA: Orphan diseases and adoptive initiatives. JAMA 290, 116.
29. KATZ, S. (2002). When the child's illness is life threatening: Impact on the parents. Pediatr. Nurs. 28, 453-463.
30. KIMMELMAN, J. (2005). Recent developments in gene transfer: Risk and ethics. BMJ 330, 79-82.
31. KING, N.M. (1999). Rewriting the "points to consider": The ethical impact of guidance document language. Hum. Gene Ther. 10, 133-139.
32. KING, N.M. (2000). Defining and describing benefit appropriately in clinical trials. J. Law Med. Ethics 28, 332-343.
33. KLAUSMEIER, W.H. (2001). A patient-supported strategy for therapy development in amyotrophic lateral sclerosis (ALS). Am. J. Ther. 8, 329-332.
34. KODISH, E., EDER, M., NOLL, R.B., RUCCIONE, K., LANGE, B., ANGIOLILLO, A., PENTZ, R., ZYZANSKI, S., SIMINOFF, L.A., and DROTAR, D. (2004). Communication of randomization in childhood leukemia trials. JAMA 291, 470-475.
35. KOHN, D.B. (2001). Gene therapy for genetic haematological disorders and immunodeficiencies. J. Intern. Med. 249, 379-390.
36. KORNFELD, M.S., and SIEGEL, I.M. (1979). Parental group therapy in the management of a fatal childhood disease. Health Soc. Work 4, 99-118.
37. KORNFELD, M.S., and SIEGEL, I.M. (1980). Parental group therapy in the management of two fatal childhood diseases: A comparison. Health Soc. Work 5, 28-34.
38. KRANISH, M. (2001). Against the odds cures for rare diseases could help us all, yet those who suffer from uncommon disorders are often left to fend for themselves. Boston Globe, August 5. http://www.boston.com/tools/archives/ (accessed August 2005).
39. LASCARI, A.D. (1978). The dying child and the family. J. Fam. Pract. 6, 1279-1286.
40. LEHMANN, V. (2001). New models for public-private partnerships in drug development. Biotechnol. Dev. Monitor 46, 2-7.
41. LIDZ, C.W., APPELBAUM, P.S., GRISSO, T., and RENAUD, M. (2004). Therapeutic misconception and the appreciation of risks in clinical trials. Soc. Sci. Med. 58, 1689-1697.
42. LUM, J. (2005). StemCells, inc. issues FDA update on proposed clinical trial. Available at URL http://www.hypeandhope.com/wt/page/index/it_1112288500 (accessed August 2005).
43. MARSHALL, E. (2000). Ethicist named in gene therapy suit. Science-NOW 3.
44. MCDONALD, J., and MARCIEL, K. (2003). NIH establishes rare diseases clinical research network. NIH News, November 3. Available at URL http://www.nih.gov/news/pr/nov2003/ncrr-03.htm (accessed August 2005).
45. MERZ, J.F., MAGNUS, D., CHO, M.K., and CAPLAN, A.L. (2002). Protecting subjects' interests in genetics research. Am. J. Hum. Genet. 70, 965-971.
46. MILLER, F.G., and BRODY, H. (2003). A critique of clinical equipoise: Therapeutic misconception in the ethics of clinical trials. Hastings Center Rep. 33, 19-28.
47. MITCHELL, E. (2005). One family challenge, for children with a rare disorder, medical answers don't come easily. Newsday, February 15. http://pqasb.pqarchiver.com/newsday/search.html (accessed August 2005).
48. OBERMAN, M., and FRADER, J. (2003). Dying children and medical research: Access to clinical trials as benefit and burden. Am. J. Law Med. 29, 301-317.
49. ORLIC, D. (2004). The strength of plasticity: Stem cells for cardiac repair. Int. J. Cardiol. 95(Suppl. 1), S16-S19.
50. POLLACK, A. (2005). Investing for a profit and a daughter's health. New York Times, March 19. http://query.nytimes.com/search/advanced (accessed August 2005).
51. RAPER, S.E., WILSON, J.M., YUDKOFF, M., ROBINSON, M.B., YE, X., and BATSHAW, M.L. (1998). Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J. Inherit. Metab. Dis. 21(Suppl. 1), 119-137.
52. ROBINSON, P. (2005). Mum's cash bid to help sick son. Yorkshire Evening Post.
53. ROWLAND, L.P. (2004). His brother's keeper: A story from the edge of medicine [Book Reviews]. N. Engl. J. Med. 350, 2012-2013.
54. SCHAEFFER, M.H., KRANTZ, D.S., WICHMAN, A., MASUR, H., REED, E., and VINICKY, J.K. (1996). The impact of disease severity on the informed consent process in clinical research. Am. J. Med. 100, 261-268.
55. SHATZ, D. (1990). Randomized clinical trials and the problem of suboptimal care: An overview of the controversy. Cancer Invest. 8, 191-205.
56. SIMON, C.M., SIMINOFF, L.A., KODISH, E.D., and BURANT, C. (2004). Comparison of the informed consent process for randomized clinical trials in pediatric and adult oncology. J. Clin. Oncol. 22, 2708-2717.
57. SMITS, A.M., VAN VLIET, P., HASSINK, R.J., GOUMANS, M.J., and DOEVENDANS, P.A. (2005). The role of stem cells in cardiac regeneration. J. Cell. Mol. Med. 9, 25-36.
58. STEINFELD, R., HEIM, P., VON GREGORY, H., MEYER, K., ULLRICH, K., GOEBEL, H.H., and KOHLSCHUTTER, A. (2002). Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutations. Am. J. Med. Genet. 112, 347-354.
59. SURBEK, D.V., GRATWOHL, A., and HOLZGREVE, W. (1999). In utero hematopoietic stem cell transfer: Current status and future strategies. Eur. J. Obstet. Gynecol. Reprod. Biol. 85, 109-115.
60. SVENDSEN, C.N., and LANGSTON, J.W. (2004). Stem cells for Parkinson disease and ALS: Replacement or protection? Nat. Med. 10, 224-225.
61. TROUILLER, P., OLLIARO, P., TORREELE, E., ORBINSKI, J., LAING, R., and FORD, N. (2002). Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 359, 2188-2194.
62. WEINER, J. (2004). His Brother's Keeper: A Story from the Edge of Medicine. (HarperCollins, New York).
63. WILLIAMS, R.E., GOTTLOB, I., LAKE, B.D., GOEBEL, H.H., WINCHESTER, B.C., and WHEELER, R.B. (1999). CLN2: Classic late infantile NCL. In The Neuronal Ceroid Lipofuscinoses. H.H. Goebel, S.E. Mole, and B.D. Lake, eds. (IOS Press, Amsterdam), pp. 37-38.
64. WINERIP, M. (1998). Fighting for Jacob. New York Times Magazine, December 6. http://query.nytimes.com/search/advanced (accessed August 2005).
65. WISNIEWSKI, K.E., KIDA, E., CONNELL, F., and ZHONG, N. (2000). Neuronal ceroid lipofuscinoses: Research update. Neurol. Sci. 21(Suppl. 3), S49-S56.